We use cookies and similar technologies to improve your experience, serve personalized ads, and analyze traffic. You can manage your preferences or accept/reject all.
Cookie Preferences
EssentialRequired for the site to function. Always active.
AnalyticsHelp us understand how visitors interact with the site.
AdvertisingUsed to deliver personalized ads.
FunctionalEnable enhanced functionality and personalization.
Markets · Investing · Business
Finance
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.
The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.
Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
What moved overnight · what to watch today · pre-positioning notes from our desk. Delivered to your inbox at 6:30 AM Dubai.
No spam. Unsubscribe in one click. We never sell your email.
We use cookies and similar technologies to improve your experience, serve personalized ads, and analyze traffic. You can manage your preferences or accept/reject all.
Cookie Preferences
EssentialRequired for the site to function. Always active.
AnalyticsHelp us understand how visitors interact with the site.
AdvertisingUsed to deliver personalized ads.
FunctionalEnable enhanced functionality and personalization.